HOPKINTON, Mass., May 23, 2011 /PRNewswire/ -- Olympus Biotech, an Olympus Corporation company, today announced the appointment of Oliver Burckhardt to the position of president of Olympus Biotech Corporation. In his new role, Mr. Burckhardt will lead the company's North American business and focus on expanding opportunities for the emerging regenerative medicine market. Mr. Burckhardt will also become a member of the Olympus Biotech Board of Directors.
"With nearly 20 years in the medical device industry, Oliver's extensive knowledge of the industry and global leadership experience will prove invaluable as we continue to grow Olympus Biotech," said Hitoshi Mizuno, CEO Olympus Biotech Corporation. "We look forward to benefiting from his immense expertise as we continue to lead the creation of this dynamic new field of medicine."
Before joining Olympus Biotech, Mr. Burckhardt most recently served as the international president and CEO of Scient'x Corp in Paris, France, where his strategic vision redefined the company's direction and resulted in double-digit growth. Mr. Burckhardt also served as president of Orthofix, Inc., where he was responsible for the global spine business unit. Prior to that, Mr. Burckhardt spent nine years with Aesculap, Inc. in various sales and marketing positions, including vice president of sales and marketing for the Aesculap Spine division in the United States.
"The Vision of Olympus Biotech to advance into regenerative medicine is the next logical step in the treatment of many medical pathologies and conditions. I am excited about the overall strategic thinking and the assets that are already in place, within Olympus, which represent a perfect starting point for this future oriented strategy," said Mr. Burckhardt. He added, "I look forward to joining the talented team at Olympus Biotech and leveraging my experience in the industry to generate further growth and success."
About Olympus Biotech Cor
|SOURCE Olympus Biotech Corporation|
Copyright©2010 PR Newswire.
All rights reserved